Novel “SMARTer” Clinical Trial Design Improves Odds of Approval and Can Reduce Study Size By Over 80%: Modeling Use of a ctDNA “Optimizing Diagnostic” for Early Therapy Switching in Immuno-Oncology Trials

Floyd Elliot Taub, Dexiang Gao
doi: https://doi.org/10.1101/2023.02.20.23286152

Article Information

doi 
https://doi.org/10.1101/2023.02.20.23286152
History 
  • February 24, 2023.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Floyd Elliot Taub1,* and
  2. Dexiang Gao2
  1. 1aiGENE, Inc.
  2. 2University of Colorado
  1. ↵*Corresponding author; email: floydtaub{at}a-i-gene.com
Back to top
Posted February 24, 2023.
Download PDF
Data/Code
Email
Novel “SMARTer” Clinical Trial Design Improves Odds of Approval and Can Reduce Study Size By Over 80%: Modeling Use of a ctDNA “Optimizing Diagnostic” for Early Therapy Switching in Immuno-Oncology Trials
Floyd Elliot Taub, Dexiang Gao
medRxiv 2023.02.20.23286152; doi: https://doi.org/10.1101/2023.02.20.23286152
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area